RESUMEN
During 2013-2017, 620 cases of Candida auris were reported in the European Union/European Economic Area - 466 (75.2%) colonisations, 110 (17.7%) bloodstream infections, 40 (6.5%) other infections and four cases (0.6%) of unknown colonisation/infection status - the majority from four large outbreaks. Survey results showed that several countries lacked laboratory capacity and/or information on the occurrence of cases at national level. To prevent further spread, adequate laboratory capacity and infection control preparedness is required in Europe.
Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidiasis/diagnóstico , Candidiasis/epidemiología , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/epidemiología , Brotes de Enfermedades , Unión Europea/estadística & datos numéricos , Control de Infecciones/métodos , Laboratorios/normas , Antifúngicos/farmacología , Candida/clasificación , Candida/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Candidiasis/microbiología , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Farmacorresistencia Fúngica Múltiple , Europa (Continente)/epidemiología , Humanos , Incidencia , Pruebas de Sensibilidad Microbiana , PrevalenciaRESUMEN
We evaluated the use of the molecular bacterial load (MBL) assay, for measuring viable Mycobacterium tuberculosis in sputum, in comparison with solid agar and liquid culture. The MBL assay provides early information on the rate of decline in bacterial load and has technical advantages over culture in either form.